Guardant Health (GH)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Guardant Health (GH)
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Key Insights
Critical company metrics and information
Share Price
$37.27Market Cap
$4.60 BillionTotal Outstanding Shares
123.56 Million SharesTotal Employees
1,779Dividend
No dividendIPO Date
October 4, 2018SIC Description
Services-medical LaboratoriesHomepage
https://www.guardanthealth.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Exchange Gains/Losses | $1.90 Million |
Net Cash Flow From Operating Activities, Continuing | $-51.06 Million |
Net Cash Flow From Financing Activities | $-2.88 Million |
Net Cash Flow From Investing Activities, Continuing | $-294.83 Million |
Net Cash Flow From Operating Activities | $-51.06 Million |
Net Cash Flow | $-346.87 Million |
Net Cash Flow From Investing Activities | $-294.83 Million |
Net Cash Flow From Financing Activities, Continuing | $-2.88 Million |
Net Cash Flow, Continuing | $-348.77 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Research and Development | $87.31 Million |
Costs And Expenses | $308.80 Million |
Income/Loss From Continuing Operations After Tax | $-107.75 Million |
Revenues | $191.48 Million |
Operating Expenses | $308.80 Million |
Basic Average Shares | $123.05 Million |
Diluted Average Shares | $123.05 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-107.75 Million |
Operating Income/Loss | $-117.33 Million |
Net Income/Loss | $-107.75 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Other Operating Expenses | $221.50 Million |
Benefits Costs and Expenses | $299.20 Million |
Income/Loss From Continuing Operations Before Tax | $-107.72 Million |
Net Income/Loss Attributable To Parent | $-107.75 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income Tax Expense/Benefit | $30000.00 |
Basic Earnings Per Share | $0.88 |
Diluted Earnings Per Share | $0.88 |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $1.23 Billion |
Equity Attributable To Parent | $-60.10 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Liabilities | $197.34 Million |
Intangible Assets | $7.25 Million |
Fixed Assets | $125.17 Million |
Liabilities | $1.60 Billion |
Other Current Liabilities | $181.87 Million |
Liabilities And Equity | $1.54 Billion |
Inventory | $72.30 Million |
Noncurrent Liabilities | $1.40 Billion |
Accounts Payable | $15.47 Million |
Equity | $-60.10 Million |
Assets | $1.54 Billion |
Noncurrent Assets | $312.01 Million |
Other Current Assets | $1.15 Billion |
Other Non-current Assets | $179.59 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.